scholarly article | Q13442814 |
P356 | DOI | 10.1007/S00415-018-9140-0 |
P698 | PubMed publication ID | 30511098 |
P50 | author | Nobuo Sanjo | Q52739848 |
P2093 | author name string | Takanori Yokota | |
Yoshiki Sekijima | |||
Toru Tanizawa | |||
Hitoshi Aizawa | |||
Yukiko Shishido-Hara | |||
Saneyuki Mizutani | |||
Yurie Nose | |||
P2860 | cites work | Effects of chloroquine, mefloquine and quinine on natural killer cell activity in vitro. An analysis of the inhibitory mechanism | Q41915149 |
Failure of mefloquine therapy in progressive multifocal leukoencephalopathy: report of two Japanese patients without human immunodeficiency virus infection | Q45353752 | ||
Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients | Q45406699 | ||
Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy | Q45510977 | ||
Expression of JC virus agnoprotein in progressive multifocal leukoencephalopathy brain | Q45731817 | ||
Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy | Q45752835 | ||
HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy | Q47727845 | ||
CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients. | Q50950889 | ||
Promyelocytic leukemia nuclear bodies provide a scaffold for human polyomavirus JC replication and are disrupted after development of viral inclusions in progressive multifocal leukoencephalopathy. | Q52586074 | ||
T cell deficiencies as a common risk factor for drug associated progressive multifocal leukoencephalopathy. | Q52689312 | ||
Fingolimod-associated PML with mild IRIS in MS: A clinicopathologic study. | Q55278001 | ||
Clinical Course and Prognostic Factors of Progressive Multifocal Leukoencephalopathy in Patients Treated with Highly Active Antiretroviral Therapy | Q58204816 | ||
Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc in a patient with idiopathic CD4 lymphocytopenia | Q59357367 | ||
Cellular and humoral immune response in progressive multifocal leukoencephalopathy | Q73892409 | ||
Progressive multifocal leukoencephalopathy | Q85179611 | ||
Progressive multifocal leukoencephalopathy: current treatment options and future perspectives | Q26776236 | ||
Restoring function in exhausted CD8 T cells during chronic viral infection | Q28289222 | ||
PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section | Q30613846 | ||
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis | Q33893285 | ||
Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy | Q34145082 | ||
Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment | Q34857689 | ||
Acute and chronic B cell depletion disrupts CD4+ and CD8+ T cell homeostasis and expansion during acute viral infection in mice | Q34909225 | ||
Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy | Q35675602 | ||
JC virus load in cerebrospinal fluid and transcriptional control region rearrangements may predict the clinical course of progressive multifocal leukoencephalopathy. | Q35899152 | ||
Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment | Q36422505 | ||
Differences in regulatory sequences of naturally occurring JC virus variants | Q36904520 | ||
A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes | Q37135539 | ||
JC virus VP1 loop-specific polymorphisms are associated with favorable prognosis for progressive multifocal leukoencephalopathy | Q37183930 | ||
Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals. | Q37492573 | ||
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases | Q37714089 | ||
Imaging manifestations of progressive multifocal leukoencephalopathy | Q37745226 | ||
Progressive multifocal leukoencephalopathy and promyelocytic leukemia nuclear bodies: a review of clinical, neuropathological, and virological aspects of JC virus-induced demyelinating disease | Q37750534 | ||
Progressive multifocal leukoencephalopathy and newer biological agents | Q37798242 | ||
The expanding family of regulatory B cells. | Q38526835 | ||
Identification and characterization of mefloquine efficacy against JC virus in vitro | Q39877627 | ||
Progressive Multifocal Leukoencephalopathy with Balanced CD4/CD8 T-Cell Infiltration and Good Response to Mefloquine Treatment. | Q40701415 | ||
Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome | Q41906877 | ||
Effect of antimalarial drugs on stimulation and interleukin 2 production of human lymphocytes | Q41914397 | ||
P433 | issue | 2 | |
P921 | main subject | progressive multifocal leukoencephalopathy | Q704930 |
P304 | page(s) | 369-377 | |
P577 | publication date | 2018-12-03 | |
P1433 | published in | Journal of Neurology | Q6295649 |
P1476 | title | A controlled inflammation and a regulatory immune system are associated with more favorable prognosis of progressive multifocal leukoencephalopathy | |
P478 | volume | 266 |
Q89520913 | Checkpoint inhibitors and progressive multifocal leukoencephalopathy: friends of foes? |
Q92321106 | Inflammatory Cerebellar PML with a CD4/CD8 Ratio of 2.9 Showed a Favorable Prognosis in a Patient with Rheumatoid Arthritis |
Q91830971 | Progressive Multifocal Leukoencephalopathy: Current Insights |
Search more.